Bausch+Lomb Results Presentation Deck
Pipeline and Upcoming Milestones¹
Ophthalmic Pharmaceuticals
Product
VYZULTA® geo-expansion
NOV032 (dry eye disease associated with
meibomian gland dysfunction)
XIPEREⓇ
Biosimilar candidate for Lucentis®
(ranibizumab) ³
Microdose formulation of atropine ophthalmic
solution (reduction of pediatric myopia
progression in children ages 3-12)4
BAUSCH + LOMB
Status
Launched in 15 countries
FDA accepted NDA in September 2022
Launched in U.S
Working with Stada/Xbrane to review
additional data requested by FDA
Clinical material supply improved
and supports re-opening enrollment
1. See slide 1 for further information on forward-looking statements.
2. In 2019, the Company acquired an exclusive license from Novaliq GmbH for the commercialization and development of NOV03 in the
United States and Canada.
3. Exclusive licensing agreement with STADA Arneimittel AG and Xbrane Biopharma AB for U.S. and Canada.
Upcoming Milestone
Expected to launch in ~10 additional countries
in 2023+
PDUFA date June 28, 2023
Canada filing expected 1023
Filed in Canada in 1Q23
Resubmission planned for 1Q23
Due to reduced clinical trial material availability
in 2022, enrollment completion is delayed from
4Q22 to 1H23.
4. Exclusive licensing agreement with Eyenovia, Inc. for U.S. and Canada.
31View entire presentation